Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Gilead 1Q Net Slips 32% On Higher Expenses, Weaker Margins

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 10:54pm CEST

Gilead Sciences Inc. (>> Gilead Sciences, Inc.) first-quarter earnings slid 32% as the biopharmaceutical company reported higher expenses and weaker margins, though adjusted profits improved.

Product sales, which generate the majority of the company's revenue, have been rising steadily in recent quarters. In the latest period, product sales rose 19%. Sales of antiviral products, its dominant revenue stream, increased 18 as HIV drugs Atripla and Truvada saw sales gains of 19% and 13%, respectively.

The company also receives royalties for Tamiflu from Roche Holding AG (RHHBY, ROG.VX). Royalty, contract and other revenue from collaborations were also up 19% last quarter.

Lately, Gilead has been focusing on simplifying HIV therapy, a treatment market that it dominates. In December, U.S. regulators accepted Gilead's new drug application for its Quad combination HIV drug, which analysts view as a potential growth driver. The Food and Drug Administration in February also granted Truvada a priority-review schedule, advancing what could become the first treatment labeled for HIV prevention.

Earlier this year, Gilead bought Pharmasset Inc. for more than $11 billion in a deal expected to accelerate the development of treatments for hepatitis C, a hotly contested market. A key drug candidate it obtained with Pharmasset, GS-7977, suffered a setback in February as a majority of hepatitis-C patients in one arm of a clinical trial had a relapse, raising questions about the drug's potential.

In the latest quarter, Gilead posted a profit of $442 million, or 57 cents a share, down from $651.1 million, or 80 cents a share, a year earlier. Excluding acquisition-related expenses, restructuring and stock-based compensation, earnings rose to 91 cents from 87 cents.

Revenue gained 19% to $2.28 billion.

Analysts polled by Thomson Reuters had expected a profit of 93 cents a share and revenue of $2.2 billion.

Operating margin narrowed to 35.1% from 46.8% as total costs and expenses jumped 45%.

Shares were down 1.4% to $52 after-hours. Through the close, the stock is up 29% since the start of the year.

 
   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com 

Stocks mentioned in the article : Gilead Sciences, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES, INC.
03/28 HUMANITARIAN ORGANIZATIONS CHALLENGE : GILD) Sovaldi Patent
03/21 GILEAD SCIENCES : British Columbia lists EPCLUSA™ on public drug plan to t..
03/20 GILEAD SCIENCES : EPCLUSA™, to treat all six genotypes of chronic hepatiti..
03/14 GILEAD SCIENCES, INC. : ex-dividend day
03/09 GILEAD SCIENCES : to Present at the Barclays Global Healthcare Conference on Tue..
03/09 GILEAD SCIENCES : Reports on Medicinal Chemistry Findings from Gilead Sciences P..
03/07 Drugmaker shares slip as Trump tweets about pricing system
03/02 GILEAD SCIENCES : New Findings from Gilead Sciences Yields New Data on B-Cell Ly..
02/28 GILEAD SCIENCES : to Present at the Barclays Global Healthcare Conference on Tue..
02/27 GILEAD SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
More news
Sector news : Bio Therapeutic Drugs
05:01p China's Creat makes 1.2 billion euro bid for German blood plasma firm
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12:30p High Medicare Part D Drug Prices Are Inflating Pharmaceutical Industry Profit..
03/29 DIVGRO PULSE : March 2017
03/28 Most Undervalued Stocks Of The S&P 500 - March 2017
03/27 My Favorite Biotech Takeover Play
03/27 Will Trump Send Drug Stocks Tumbling Again?
Advertisement
Financials ($)
Sales 2017 24 635 M
EBIT 2017 15 210 M
Net income 2017 10 403 M
Debt 2017 978 M
Yield 2017 3,18%
P/E ratio 2017 9,16
P/E ratio 2018 9,94
EV / Sales 2017 3,61x
EV / Sales 2018 3,93x
Capitalization 87 925 M
More Financials
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 81,5 $
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-6.07%87 925
AMGEN, INC.11.52%120 086
CELGENE CORPORATION7.21%96 538
REGENERON PHARMACEUTIC..7.37%41 811
ACTELION LTD24.44%30 002
VERTEX PHARMACEUTICALS..46.61%26 834
More Results